Quick Answer
Denali Therapeutics Inc. reported Research And Development Expense of $418.78 million for the year ending 2025.
- Denali Therapeutics Inc. showed an increase of +5.6% in Research And Development Expense from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Denali Therapeutics Inc.'s Research And Development Expense has grown by 453.2%.
- Historical annual values: Fiscal year 2025: $418.78 million | Fiscal year 2024: $396.44 million | Fiscal year 2023: $423.88 million | Fiscal year 2022: $358.73 million | Fiscal year 2021: $265.35 million | Fiscal year 2020: $212.62 million | Fiscal year 2019: $193.38 million | Fiscal year 2018: $143.18 million | Fiscal year 2017: $74.46 million | Fiscal year 2016: $75.70 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: